Zanubrutinib Clinical Outcomes in B-Cell Malignancies: Latest Evidence from Phase II and III Trials
B-cell malignancies are a heterogeneous group of hematological cancers such as Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma and Waldenström Macroglobulinemia. Although these diseases have diverse clinical manifestations and courses, they share numerous common underlying molecular pathways resulting from dysregulated B-cell receptor (BCR) signaling. Targeted therapies that act on these signaling pathways have been investigated in […]









